Table 1 Summary of clinical characteristics and genomic findings

#02

36.8

5

3bN1

P 8

SV 1

 + FFPE samples:

LN 3

3 years

PPP. Nodal and bone metastases. On ADT + chemotherapy (Docetaxel)

Branching evolution in the prostate. Evolution driven primarily by SNVs; polyclonal SV sample

#08

6.50

5

3bN1

P 6

SV 2

3 years

PPP. Residual pelvic lymph node disease. On ADT + chemotherapy (Docetaxel)

Branching evolution in the prostate. Evolution driven by a number of CNAs in addition to SNVs; FOXP1 deletion in clone spreading to SV; polyclonal SV

#10

5.08

3 (with amphicrine differentiation)

3bN1

P 5

LN 4

SV 0

 + FFPE samples:

P 3

SV 1

3 years

PPP. Widespread lymph node metastases on CT. On ADT + chemotherapy (Cisplatin/Etoposide)

Branching evolution in the prostate. Amphicrine prostate cancer evolved from Adenocarcinoma;

#13

46.30

3

3bN1

P 5

LN 1

3 years

Recurrent pelvic lymph node and bone metastases. On ADT + chemotherapy (Docetaxel)

Branching evolution in the prostate. No notable histological heterogeneity

#15

6.83

5

3aN1

P 2

LN 2

3 years

Salvage pelvic radiotherapy for rising PSA to 0.29. PSMA-PET negative

Branching evolution in the prostate. Whole genome doubling; chromoplexy; increased SBS3